Heparin and heparinoids prevent the binding of immune complexes containing nucleosomal antigens to the GBM and delay nephritis in MRL/lpr mice

Kidney International

Volumn 50, Issue 5, 1996, Pages 1555-1564

  Van Bruggen, Mieke C J ^a   Walgreen, Birgitte ^b   Rijke, Truus P M ^b   Corsius, Marc J A M M ^b   Assmann, Karel J M ^b   Smeenk, Ruud J T ^b   Van Dedem, Gijs W K ^b   Kramers, Kees ^b   Berden, Jo H M ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HEPARAN SULFATE; HEPARIN; HEPARINOID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CONTROLLED STUDY; GLOMERULUS BASEMENT MEMBRANE; IMMUNE COMPLEX NEPHRITIS; IMMUNOFLUORESCENCE; MOUSE; NONHUMAN; NUCLEOSOME; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0029855958     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1038/ki.1996.471     Document Type: Article

References (50)

1. KRAMERS C, HYLKEMA MN, VAN BRUGGEN MCJ, VAN DE LAGEMAAT R, DijKMAN HBPM, ASSMANN KJM, SMEENK RJT, BERDEN JHM: Anti-nucleosome antibodies complexed to nucleosomal antigens show anti-DNA reactivity and bind to rat glomerular basement membrane in vivo. J Clin Invest 94:568-577, 1994
2. TERMAAT RM, ASSMANN KJM, DIJKMAN HBPM, SMEENK RJT, BERDEN JHM: Anti-DNA antibodies can bind to the glomerulus via two distinct mechanisms. Kidney Int 42:1363-1371, 1992
3. TERMAAT RM, BRINKMAN K, VAN GOMPEL F, VAN DE HEUVEL LPWJ, VEERKAMP J, SMEENK RJT, BERDEN JHM: Cross-reactivity of monoclonal anti-DNA antibodies with heparan sulfate is mediated via bound DNA/histone complexes. J Autoimmunity 3:531-545, 1990
4. JACQUES LB: Heparin: An old drug with a new paradigm. Science 206:528-533, 1979
5. PURKERSON ML, JOIST JH, GREENBERG JM, KAY D, HOFFSTEN PE, KLAHR S: Inhibition by anticoagulant drugs of the progressive hypertension and uremia associated with renal infarction in rats. Thromb Res 26:227-240, 1982
6. PURKERSON ML, HOFFSTEN PE, KLAHR S: Pathogenesis of the glomerulopathy associated with renal infarction in rats. Kidney Int 9:407-417, 1976
7. PURKERSON ML, TOLLEFSEN DM, KLAFIR S: N-desulfated/acetylated heparin ameliorates the progression of renal disease in rats with subtotal renal ablation. J Clin Invest 81:69-74, 1988
8. OLSON JL: Role of heparin as a protective agent following reduction of renal mass. Kidney Int 25:376-382, 1984
9. NAPARSTEK Y, BEN-YEHUDA A, MADAIO MP, BAR-TANA R, SCHUGER L, PIZOV G, NEEMAN Z, COHEN IR: Binding of anti-DNA antibodies and inhibition of glomerulonephritis in MRL-lpr/lpr mice by heparin. Arthritis Rheum 33:1554-1559, 1990
10. DIAMOND JR, KARNOVSKY MJ: Nonanticoagulant protective effect of heparin in chronic aminonucleoside nephrosis. Renal Physiol 9:366-374, 1986
11. WILSON SK, SOLEZ K, BOITNOTT JK, HEPTINSTALL RH: The effects of heparin treatment on hypertension and vascular lesions in stroke-prone spontaneously hypertensive rats. Am J Pathol 102:62-71, 1981
12. MANDAL AK, LYDEN TW, SAKLAYEN MG: Heparin lowers blood pressure: Biological and clinical perspectives. Kidney Int 47:1017-1022, 1995
13. INOUE Y, NAGASAWA K: Selective N-desulfation of heparin with dimethyl sulfoxide containing water or methanol. Carbohydr Res 46:87-95, 1976
14. HIRANO S, OHASHI W: N-acetylation of N-desulfated heparin. Agr Biol Chem 40:2501-2502, 1976
15. CASU B, GENNARO U: A conductimetric method for the determination of sulphate and carboxyl groups in heparin and other mucopolysaccharides. Carbohydr Res 39:168-176, 1975
16. CASU B: Structure and biological activity of heparin and other glycosaminoglycans. Pharmacol Res Commun 11:1-18, 1979
17. TEIEN AN, LIE M, ABILDGAARD U: Assay of heparin in plasma using a chromogenic substrate for activated factor X. Thromb Res 8:413-416, 1976
18. LARSEN ML, ABILDGAARD U, TEIEN AN, GJESDAL K: Assay of plasma heparin using thrombin and the chromogenic substrate H-D-Phe-Pip-Arg-pNA (S-2238). Thromb Res 13:285-288, 1978
19. FISCHER J, VERBRUGGEN B, WESSELS H, HAANEN C: Interference of coumarin therapy with the "Heptest" owing to declining prothrombin concentrations. Clin Chem 35:483-486, 1989
20. HYLKEMA MN, KRAMERS C, VAN DEN WAL THJ, VAN BRUGGEN MCJ, SWAAK AJG, BERDEN JHM, SMEENK RJT: A new ELISA for the detection of anti-heparan sulfate reactivity, using photobiotinylated antigen. J Immunol Meth 176:33-43, 1994
21. ASSMANN KJM, TANGELDER MM, LANGE WPJ, SCHRIJVER G, KOENE RAP: Anti-GBM nephritis in the mouse: Severe proteinuria in the heterologous phase. Virchows Arch A 406:285-300, 1985
22. VAN BRUGGEN MCJ, KRAMERS C, HYLKEMA MN, VAN DEN BORN J, BARKER MAH, ASSMANN KJM, SMEENK RJT, BERDEN JHM: Decrease of heparan sulfate staining in the glomerular basement membrane in murine lupus nephritis. Am J Pathol 146:753-763, 1995
23. BERDEN JH, FAABER P, ASSMANN KJ, RIJKE TP: Effects of cyclosporin A on autoimmune disease in MRL/1 and BXSB mice. Scand J Immunol 24:405-411, 1986
24. CASTELLOT JJJ, HOOVER RL, HARPER PA, KARNOVSKY MJ: Heparin and glomerular epithelial cell-secreted heparin-like species inhibit mesangial-cell proliferation. Am J Pathol 120:427-435, 1985
25. WOLTHUIS A, BOES A, BERDEN JH, GROND J: Heparins modulate extracellular matrix and protein synthesis of cultured rat mesangial cells. Virchows Arch B 63:181-189, 1993
26. CAENAZZO C, GARBISA S, CEOL M, BAGGIO B, BORSATTI A, MARCHI E, GAMBARO G: Heparin modulates proliferation and proteoglycan biosynthesis in murine mesangial cells: Molecular clues for its activity. Nephrol Dial Transplant 10:175-184, 1995
27. WANG A, FAN MY, TEMPLETON DM: Growth modulation and proteoglycan turnover in cultured mesangial cells. J Cell Physiol 159:295-310, 1994
28. COFFEY AK, KARNOVSKY MJ: Heparin inhibits mesangial cell proliferation in habu-venom-induced glomerular injury. Am J Pathol 120: 248-255, 1985
29. FLOEGE J, ENG E, YOUNG B, COUSER WG, JOHNSON RJ: Heparin suppresses mesangial cell proliferation and matrix expansion in experimental mesangioproliferative glomerulonephritis. Kidney Int 43: 369-380, 1993
30. ADLER S: Inhibition of rat glomerular visceral epithelial cell growth by heparin. Am J Physiol 255:F781-F786, 1988
31. DRAKELEY SJ, FURNESS PN: Heparin inhibits the binding of immune complexes to cultured rat mesangial cells. Nephrol Dial Transplant 9:1084-1089, 1994
32. MATTANA J, SINGHAL PC: Heparin attenuates the effect of mitogenic vasoconstrictors on mesangial cell proliferation and handling of immunoglobulin G complexes. J Pharmacol Exp Ther 273:80-87, 1995
33. GORSKI A, WASIK M, STEPIEN-SOPNIEWSKA B, GLAPINSKI T: Heparin and platelet interactions influence alloantigen-induced proliferative responses of human T lymphocytes and immunoglobulin synthesis in vivo. Immunol Lett 28:161-165, 1991
34. GORSKI A, WASIK M, NOWACZYK M, KORCZAK-KOWALSKA G: Immunomodulating activity of heparin. FASEB J 5:2287-2291, 1991
35. LIDER O, MEKORI YA, MILLER T, BAR-TANA R, VLODAVSKY I, BAHARAV E, COHEN IR, NAPARSTEK Y: Inhibition of T lymphocyte heparanase by heparin prevents T cell migration and T cell-mediated immunity. Eur J Immunol 20:493-499, 1990
36. LIDER O, BAHARAV E, MEKORI YA, MILLER T, NAPARSTEK Y, VLODAVSKY I, COHEN IR: Suppression of experimental autoimmune diseases and prolongation of allograft survival by treatment of animals with low doses of heparins. J Clin Invest 83:752-756, 1989
37. TERMAAT RM, BRINKMAN K, NOSSENT JC, SWAAK AJG, SMEENK RJT, BERDEN JHM: Anti-heparan sulphate reactivity in sera from patients with systemic lupus erythematosus with renal or non-renal manifestations. Clin Exp Immunol 82:268-274, 1990
38. KRAMERS C, TERMAAT RM, TER BORG EJ, VAN BRUGGEN MCJ, KALLENBERG CGM, BERDEN JHM: Higher anti-heparan sulphate reactivity during SLE exacerbations with renal manifestations. A long term prospective analysis. Clin Exp Immunol 93:34-38, 1993
39. FILLIT H, LAHITA R: Antibodies to vascular heparan sulfate proteoglycan in patients with systemic lupus erythematosus. Autoimmunity 9:159-164, 1991
40. SHIBATA S, SASAKI T, HARPEL P, FILLIT H: Autoantibodies to vascular heparan sulfate proteoglycan in systemic lupus erythematosus react with endothelial cells and inhibit the formation of thrombin-antithrombin III complexes. Clin Immunol Immunopathol 2:114-123, 1994
41. EDENS RE, LINHARDT RJ, BELL CS, WEILER JM: Heparin and derivatized heparin inhibit zymosan and cobra venom factor activation of complement in serum. Immunopharmacology 27:145-153, 1994
42. WEILER JM, EDENS RE, LINHARDT RJ, KAPELANSKI DP: Heparin and modified heparin inhibit complement activation in vivo. J Immunol 148:3210-3215, 1992
43. CAMUSSI G, TETTA C, MAZZUCCO G, MONGA G, ROFFINELLO C, ALBERTON M, DELLABONA P, MALAVASI F, VERCELLONE A: Platelet cationic proteins are present in glomeruli of lupus nephritis patients. Kidney Int 30:555-565, 1986
44. BARNES JL, LEVINE SP, VENKATACHALAM MA: Binding of platelet factor four (PF 4) to glomerular polyanion. Kidney Int 25:759-765, 1984
45. CHEN ZY, JIANG XY, FEI L: Effect of heparin on the anionic sites of glomerular basement membrane in adriamycin nephrosis in rats. Chin Med J Engl 105:671-675, 1992
46. GAMBARO G, CAVAZZANA AO, LUZI P, PICCOLI A, BORSATTI A, CREPALDI G, MARCHI E, VENTURINI AP, BAGGIO B: Glycosaminoglycans prevent morphological renal alterations and albuminuria in diabetic rats. Kidney Int 42:285-291, 1992
47. GAMBARO G, VENTURINI AP, NOONAN DM, FRIES W, RE G, GARBISA S, MILANESI C, PESARINI A, BORSATTI A, MARCHI E, BAGGIO B: Treatment with a glycosaminoglycan formulation ameliorates experimental diabetic nephropathy. Kidney Int 46:797-806, 1994
48. VAN DEN BORN J, DESASSIS JF, BERDEN JHM: Decrease of GBM heparan sulfate in adriamycin nephropathy. (abstract) J Am Soc Nephrol 3:647, 1992
49. TAMSMA JT, VAN DEN BORN J, BRUIJN JA, ASSMANN KJM, WEENING JJ, BERDEN JHM, WIESLANDER J, SCHRAMA E, HERMANS J, VEERKAMP JH, LEMKES HHPJ, VAN DER WOUDE FJ: Expression of glomerular extracellular matrix components in human diabetic nephropathy: Decrease of heparan sulfate in the glomerular basement membrane. Diabetologia 37:313-320, 1994
50. MYRUP B, HANSEN PM, JENSEN T, KOFOED-ENEVOLDSEN A, FELDT-RASMUSSEN B, GRAM J, KLUIFT C, JESPERSEN J, DECKERT T: Effect of low-dose heparin on urinary albumin excretion in insulin-dependent diabetes mellitus. Lancet 345:421-422, 1995